June 3, 2015 - Percutaneous Cardiovascular Solutions (PCS) announced it had been granted a key patent in the United States covering its percutaneous mitral valve replacement system.
United States of America Patent No. 8979922, entitled "˜Mitral Valve Prosthesis', covers the use of a percutaneous mitral valve replacement system which enables patients with severe mitral regurgitation and failing hearts to have a catheter-based minimally invasive option for valve replacement. The allowed claims include percutaneous replacement of the mitral valve, including sub-valvular fixation, as well as the method of delivery and implantation. Similar patent claims have been granted in other jurisdictions.
According to Elsevier Business Intelligence, significant mitral valve regurgitation occurs in about 2 percent of the population, with approximately 4 million people in the United States with moderate to severe mitral regurgitation. The potential market for percutaneous mitral valve repair or replacement is expected to be at least four times greater than the aortic valve replacement market.
For more information: www.uspto.gov